Catalyst
Slingshot members are tracking this event:
Ardelyx, Inc. Expected to Release Clinical Data by Mid-2017 from T3MPO-1 Trial with Tenapanor in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 12, 2017
Occurred Source:
http://ir.ardelyx.com/releasedetail.cfm?ReleaseID=1026198
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Irritable Bowel Syndrome, Ibs-c, T3mpo-1, Tenapanor, Nhe3 Inhibitor, Phase 3
